Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.

Alhalabi, Omar; Hasanov, Elshad; Wilson, Nathaniel R; Araujo, John; Wang, Jianbo; Campbell, Matthew T; Goswami, Sangeeta; Shah, Amishi Y; Gao, Jianjun; Msaouel, Pavlos; Tannir, Nizar M

Alhalabi, Omar; Hasanov, Elshad; Wilson, Nathaniel R; Araujo, John; Wang, Jianbo; Campbell, Matthew T; Goswami, Sangeeta; Shah, Amishi Y; Gao, Jianjun; Msaouel, Pavlos; Tannir, Nizar M.

Afiliação

Alhalabi O; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hasanov E; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wilson NR; Department of Internal Medicine, University of Texas Houston, McGovern Medical School, Houston, Texas, USA.
Araujo J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Campbell MT; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Goswami S; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shah AY; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gao J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Msaouel P; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tannir NM; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Int J Cancer ; 149(2): 387-393, 2021 07 15.

Article em En | MEDLINE | ID: mdl-33739450

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem; Carcinoma de Células Renais/tratamento farmacológico; Ipilimumab/administração & dosagem; Neoplasias Renais/tratamento farmacológico; Nivolumabe/administração & dosagem; Adulto; Idoso; Idoso de 80 Anos ou mais; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Determinação de Ponto Final; Feminino; Hospitalização; Humanos; Ipilimumab/efeitos adversos; Masculino; Pessoa de Meia-Idade; Metástase Neoplásica; Nivolumabe/efeitos adversos; Estudos Retrospectivos; Análise de Sobrevida; Centros de Atenção Terciária; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Ipilimumab / Nivolumabe / Neoplasias Renais Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google